The down-regulated ING5 expression in lung cancer: A potential target of gene therapy

Shuang Zhao¹, Xue-feng Yang¹, Dao-fu Shen¹, Yang Gao¹, Shuai Shi¹, Ji-cheng Wu¹, Hong-xu Liu², Hong-zhi Sun¹, Rong-jian Su³, Hua-chuan Zheng¹,3

¹Cancer Center, Key Laboratory of Brain and Spinal Cord Injury of Liaoning Province, and Animal Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121001, China
²Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China
³Life Science Institute of Jinzhou Medical University, Jinzhou, 121001, China

Correspondence to: Hua-chuan Zheng, email: zheng_huachuan@hotmail.com

Keywords: lung cancer, ING5, pathogenesis, aggressiveness, prognosis

Received: February 06, 2016 Accepted: May 28, 2016 Published: July 09, 2016

ABSTRACT

ING5 can interact with p53, thereby inhibiting cell growth and inducing apoptosis. We found that ING5 overexpression not only inhibited proliferation, migration, and invasion, but also induced G2 arrest, differentiation, autophagy, apoptosis, glycolysis and mitochondrial respiration in lung cancer cells. ING5 transfection up-regulated the expression of Cdc2, ATG13, ATG14, Beclin-1, LC-3B, AIF, cytochrome c, Akt1/2/3, ADFP, PFK-1 and PDPc, while down-regulated the expression of Bcl-2, XIAP, survivin, β-catenin and HXK1. ING5 transfection desensitized cells to the chemotherapy of MG132, paclitaxel, and SAHA, which paralleled with apoptotic alteration. ING5 overexpression suppressed the xenograft tumor growth by inhibiting proliferation and inducing apoptosis. ING5 expression level was significantly higher in normal tissue than that in lung cancer at both protein and mRNA levels. Nuclear ING5 expression was positively correlated with ki-67 expression and cytoplasmic ING5 expression. Cytoplasmic ING5 expression was positively associated with lymph node metastasis, and negatively with age, lymphatic invasion or CPP32 expression. ING5 expression was different in histological classification: squamous cell carcinoma > adenocarcinoma > large cell carcinoma > small cell carcinoma. Taken together, our data suggested that ING5 downregulation might involved in carcinogenesis, growth, and invasion of lung cancer and could be considered as a promising marker to gauge the aggressiveness of lung cancer. It might be employed as a potential target for gene therapy of lung cancer.

INTRODUCTION

Inhibitor of growth 5 (ING5) belongs to the encoding protein of Class II tumor suppressor gene (TGS) since its inactivation results from frequent genetic and epigenetic alterations [1, 2]. Structurally, it includes LZL (leucine zipper like), NCR (novel conserved region), NLS (nuclear localization signal), and PHD (plant homeo domain) domains from N-terminal to C-terminal. LZL domain has been shown to induce DNA repair, apoptosis and chromatin remodeling. NCR domain can bind to histone acetyl transferase (HAT) complexes during chromatin remodeling and gene expression [3, 4]. ING5 interacts with histone H3K4me3 to form histone H3-ING5-MOZ-MORF- BRPF and H4-ING5-HBO1-JADE HAT complexes [3–7]. The latter promotes DNA replication via the interaction with mini-chromosome maintenance protein because ING5 knockdown completely abolishes DNA synthesis, and HBO1 knockdown increases S-phase cells ratio [8]. ING5 was reported to activate the cyclin-dependent kinase inhibitor p21/waf1 promoter and acetylated ING5 subsequently bound to the promoters of its target apoptotic genes, including Bax and GADD45 [9, 10]. The antiproliferative effect of ING5 depended on its interaction with INCA1 [11]. ING5 enhanced p53 Lys-382 and Lys-120 acetylation for the pathological and physical interaction [9, 10].

ING5 overexpression can decrease colony-forming efficiency, S-phase cell population, and induce apoptosis of RKO cells in a p53-dependent manner [9]. The intact
ING5 can inhibit proliferation and induce apoptosis in HSC-3 cells, while two truncated fragments of ING5 (aa 1-184 and 107-226) induce cellular senescence with cyclin E and CDK2 hypoexpression [12]. ING5 overexpression reverses the aggressive phenotypes of gastric cancer cells such as autophagy and proliferation, dedifferentiation, migration, invasion and lamellipodia formation. ING5 overexpression activates both β-catenin and NF-κB pathways in SGC-7901 cells, and promotes the expression of down-stream genes (e.g. c-myc, Cyclin D1, survivin, and interleukins). ING5-mediated chemoresistance was closely related to their apoptotic resistance, Akt activation, and the overexpression of chemoresistance-related genes [13]. ING5 deletion was found to initiate carcinogenesis of ameloblastoma and oral cancers [14, 15]. Recently, down-regulated ING5 mRNA expression and the missense mutations of its LZL and NCR domains were detectable in oral squamous cell carcinoma [16]. The nuclear ING5 was lowly expressed in the tumorigenesis and promoted apoptosis and cell cycle arrest by interacting with p300 and p21 proteins in neck squamous cell carcinoma (HNSSCC) [17]. The nuclear to cytoplasmic shift of ING5 protein occurred during colorectal, gastric and HNSCC carcinogenesis and was positively linked to the aggressive behaviors of colorectal and gastric cancers [17–19]. ING5 overexpression suppressed growth, blood supply and lung metastasis of SGC-7901 cells by inhibiting proliferation and enhancing autophagy in xenograft models [13].

Lung cancer is one of the most common malignancies and accounts for more deaths than any other cancers in both men and women worldwide despite the increased survival of cancer patients who receive advanced chemotherapy [20, 21]. In the present study, we observed the effects of ectopic ING5 overexpression on aggressive phenotypes of lung cancer cells, and analyzed the relevant molecular mechanisms. ING5 expression was examined in lung cancers, and compared with their clinicopathological parameters. Finally, we observed the effects and mechanisms of ING5 expression on the growth of lung cancer cells using nude mice model.

RESULTS

The effects of ING5 expression on the phenotypes and their related mechanisms of lung cancer cell lines

After transfected with pEGFP-N1-ING5, A549 (adenocarcinoma) and SQ-5 (squamous carcinoma) cells overexpressed ING5 at both mRNA and protein levels (Figure 1A, p < 0.05). There was a more mitotic disruption by contrast microscopy and crystal violet staining (Figure 1B) and a slower growth evidenced by CCK-8 (Figure 1C, p < 0.05) in comparison to the control and mock. Cell cycle analysis indicated that G2 arrest in both ING5 transfectants by PI staining (Figure 1D, p < 0.05). There was a high level of apoptosis evidenced by Annexin-V (Figure 1E, p < 0.05), a high autophagy by pEGFP-tagged LC-3B transfection (Figure 1F) and a good differentiation by ALP activity (Figure 1G, p < 0.05) in ING5 transfectants, compared with the control and mock. Additionally, forced ING5 overexpression could suppress migration and invasion by wound healing or transwell chamber assay (Figure 1H and 1I, p < 0.05). There was no difference in lamellipodia formation between the control/mock and ING5 transfectants, evidenced by F-actin staining (Figure 1J). ING5-overexpressing lung cancer cells showed aberrant fat accumulation according to oil red O staining (Figure 1K), and enhanced glycolytic and mitochondrial respiration (Figure 1L, p < 0.05). Further Western-blotting showed higher expression of Cdc2, ATG13, ATG14, Beclin-1, LC-3B, AIF, cytochrome c, Akt1/2/3, ADFP, PFK-1 and PDPC in A459 and SQ-5 transfectants, but did lower expression of Bcl-2, XIAP, survivin,β-catenin and HXK1 than the control and mock (Figure 1M).

After the exposure to different anti-cancer agents (MG132, paclitaxel, and SAHA), both transfectants showed higher viability and lower apoptosis than those of the control in both time- and dose-dependent manners (Figure 2A and 2B, p < 0.05). In the nu/nu mice, ING5 suppressed the xenograft tumor growth by tumor volume and weight (Figure 3A–3E, p < 0.05), inhibited proliferation, induced apoptosis and autophagy according to immunohistochemistry and TUNEL (Figure 3F).

Association of ING5 expression with the clinicopathological parameters of lung cancers

ING5 mRNA levels was significantly higher in normal tissue than lung cancer (Figure 4A and 4B, p < 0.05), and negatively associated with tumor size of lung cancer (Figure 4D, p < 0.05). Higher ING5 mRNA expression was detected in younger patients (< 60 years) with lung cancer than the counterparts (Figure 4C, p < 0.05). ING5 mRNA was overexpressed in adenocarcinoma (Ad), in comparison to squamous cell carcinoma (Sq) and small cell carcinoma (SCC, Figure 4E, p < 0.05). The densitometric analysis showed ING5 protein overexpression in normal tissue, compared with lung cancer (Figure 5A–5C, p < 0.05). ING5 expression was not related to age or tumor size of lung cancer (Figure 5D and 5E, p > 0.05). ING5 protein was hypoxpressed in Ad, in comparison to Sq and SCC (Figure 5F, p < 0.05).

ING5 protein was detected in the cytoplasm and nucleus of pseudo-stratified columnar epithelium, alveolar epithelial cells, macrophage, squamous cell carcinoma, adenocarcinoma, large cell carcinoma and squamous cell carcinoma (Figure 6A–6I). p53, ki-67 and Caspase-3 were strongly expressed in lung cancer (Figure 6J–6L). As summarized in Table 1, nuclear ING5 expression was positively correlated with ki-67 expression and cytoplasmic ING5 expression (p < 0.05), but no relation was found.
with sex, age, lymphatic or venous invasion, lymphatic node metastasis, clinicopathological staging, CPP32 or p53 expression ($p > 0.05$). Cytoplasmic ING5 expression was positively associated with lymph node metastasis, and negatively related with age, lymphatic invasion and CPP32 expression ($p < 0.05$), but not correlated with sex, venous invasion, clinicopathological staging, ki-67 or p53 expression (Table 2, $p > 0.05$). Nuclear and cytoplasmic ING5 expression became gradually weaker from Sq, Ad, LCC (large cell carcinoma) to SCC ($p < 0.05$, Tables 1–2). Follow-up information was available on 124 patients with lung cancer for periods ranging from 1 month to 12 years (mean = 20.5 months). Univariate analysis using Kaplan-Meier method indicated that either nuclear or cytoplasmic ING5 expression was no related with the survival rate of the patients with lung cancer (Figure 6M and 6N, $p > 0.05$).

### DISCUSSION

Down-regulated expression of nuclear ING5 protein was observed in oral Sq, HNSCC and colorectal cancer (CRC) respectively [16–19]. Cytoplasmic translocation of ING5 had impact on the carcinogenesis of HNSCC and CRCs and cytoplasmic ING5 was positively correlated with the aggressive behaviors of CRC and gastric cancers [17, 18]. Here, ING5 mRNA and protein were found to decrease in lung cancer, compared with those of normal lung tissues, indicating that its deregulation might promote lung tumorigenesis. ING5 expression became gradually weaker from Sq, Ad, LCC to SCC, suggesting that ING5 might be employed as a marker to differentiate the histological subtypes of lung cancer. Consistent with another report [18], cytoplasmic ING5 was negatively associated with lymphatic
invasion of lung cancer, which might be attributable to no wide and careful application of D2-40 immunostaining in the pathological diagnosis. The positive correlation between cytoplasmic ING5 and lymph node metastasis suggested that it could be regarded as a marker for aggressiveness, supported by lower CPP32 (a apoptotic marker) in the cases with cytoplasmic ING5 positive. The positive relationship between nuclear ING5 and ki-67 (a proliferative marker) expression might be due to a feedback overexpression of nuclear ING5 in lung cancer.

Since pulmonary Ad and Sq histologically rank the first and two, we chose A549 and SQ-5 for cell functional experiments. It was that ING5 overexpression induced apoptosis, autophagy and differentiation, and inhibited the proliferation, cell mitosis and cell cycle progression, migration and invasion. In tumor-bearing nude mouse model, ING5 was demonstrated to suppress the tumor growth by inducing apoptosis and autophagy, and decreasing proliferative ability. However, it was worth noting that ING5 might induce chemoresistance, which was positively linked to apoptotic resistance, in line with a previous report [13]. In other words, ING5 up-regulated the apoptotic level of lung cancer cells, but had no ability to induce their apoptotic level against chemodrugs. In combination with the findings in gastric cancer cells, it should be possible and practicable to employ ING5 as a potential target for gene therapy of malignancies if its chemoresistance could be dislodged. Reportedly, ING5 inhibited cancer aggressiveness of lung cancer via preventing epithelial to mesenchymal transition [22], but it was regret that the phenomenon was not observed although we utilized the same cancer cell, A549.

In lung cancer cells, ectopic ING5 expression caused G$_2$ phase arrest and suppressed proliferation, while the overexpression of Cdc2 protein might be attributed to the higher proportion of cells in G$_2$ phase [23]. It is well known that Bax interacts with Bcl-2, promotes cytochrome c release, and activates the endogenous apoptosis pathway, which is abolised by survivin [24]. AIF transfers from the mitochondria to the cytoplasm, and then enters the nucleus, causing nuclear DNA aggregate and fractures [25]. ING5 overexpression up-regulated the expression of...
of pro-apoptotic proteins AIF and cytochrome c, and down-regulated the expression of anti-apoptotic proteins Bcl-2, XIAP and survivin, accounting for its apoptosis-induced role in lung cancer cells by mitochondrial pathway. Autophagy might wrap organelles and proteins in autophagic classical pathway by the complexes, including ATG13, ATG14, Beclin-1 and LC-3B [26, 27]. Here, it was found that ING5 overexpression in vivo and vitro induced the autophagy of lung cancer cells with ATG13, ATG14 and Beclin-1 overexpression, indicating that ING5-induced autophagy was dependent on Beclin-1 and belonged to canonical pathway.
Figure 2: ING5 expression weakened the sensitivity of lung cancer cells to chemotherapeutic agents. After treated with MG132, paclitaxel and SAHA, ING5 transfectants showed a higher viability (A) and a lower apoptotic level (B) than the control in both concentration-and time-dependent manners ($p < 0.05$).
Hexokinase I (HXKI) utilizes Mg\(^{2+}\)-ATP as a phosphoryl donor to catalyze the first step of intracellular glucose metabolism, the conversion of glucose to glucose-6-phosphate [28]. Phospho- fructokinases 1(PFK-1) is a regulatory glycolytic enzyme that converts fructose 6- phosphate and ATP into fructose 1, 6-bisphosphate [29]. Pyruvate dehydrogenase phosphatase c (PDP c) is localized within the mitochondrial matrix and efficiently dephosphorylates all three phosphorylation sites located on α chain of the E1 component, which simultaneously activates pyruvate dehydrogenase to convert pyruvate to acetyl-CoA for utilization in the Kreb’s Cycle [30]. Adipophilin (ADFP) is a ubiquitous component of lipid droplets and its overexpression is a useful marker for pathologies characterized by increased lipid droplet accumulation [31]. Here, we for the first time found that ING5 overexpression increased glycolysis and subsequent aerobic oxidation, which is closely linked to PFK-1 and PDPc overexpression. Additionally, aberrant fat accumulation in ING5 transfectants might be attributable to the up-regulatory ADFP expression.

In summary, down-regulation expression of ING5 protein could be involved in lung carcinogenesis and closely linked to the histogenesis of non-small cell lung cancers. ING5 overexpression might suppress the proliferation, migration and invasion, induce apoptosis, autophagy, and differentiation, and mediate chemotherapeutic resistance of lung cancer cells. Therefore, it has to be possible to employ ING5 as a target of gene therapy for lung cancer if its chemoresistance could be overcome. We for the first time reported that ING5 might induce glucose catabolism and aberrant fat deposition in lung cancer cells.

**MATERIALS AND METHODS**

**Cell culture and transfection**

Lung cancer cell lines, A549 and SQ-5 came from Japanese Physical and Chemical Institute. They were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and...
100 μg/ml streptomycin in an atmosphere of 5% CO$_2$ at 37°C. The cells were collected by centrifugation and rinsed with phosphate buffered saline (PBS, pH 7.2) for RNA and protein extract.

**Crystal violet and oil red O staining**

To observe the morphological appearance, we fixed cells in 100% methanol for 20 min and stained with crystal violet. At aim to identify the fat accumulation, the cells were fixed in ice cold 10% formalin for 30 min and rinsed with PBS for three times. After that, the plates were incubated with pre-warmed Oil Red O solution for 15 min.

**Proliferation assay**

Cell Counting Kit-8 (CCK-8) was employed to determine cell viability. In brief, 2.0 × 10$^3$ cells/well were seeded on 96-well plate and allowed to adhere. At different time points, 10 μL of CCK-8 solution was added into each well and the plates were incubated for 3 h in the incubator, and then measured at 450 nm.

**Cell cycle analysis**

The cells were trypsinized, collected, washed by PBS twice and fixed in cold 10 mL ethanol for more than 2 h at −20°C. And then, cells were washed by PBS twice

![Figure 4: The correlation of ING5 mRNA expression with clinicopathological features of lung cancers.](image-url)

**Figure 4**: The correlation of ING5 mRNA expression with clinicopathological features of lung cancers. ING5 mRNA was quantified normal lung tissue (N, n = 18) and lung cancers (C, n = 72) with GAPDH as an internal control by real-time PCR (A). ING5 mRNA expression level was significantly higher in normal tissue than lung cancer (B, p < 0.05), and negatively associated with tumor size of lung cancer (D, p < 0.05). Higher ING5 mRNA expression was detected in younger patients (< 60 years) with lung cancer than the counterparts (C, p < 0.05). ING5 mRNA was overexpressed in adenocarcinoma, in comparison to squamous cell carcinoma and small cell carcinoma (E, p < 0.05). The data is expressed as mean ± standard error; *p < 0.05.
and incubated with 1 mL RNase (0.25 mg/mL) at 37°C for 1 h. The cells were pelleted and resuspended in propidium iodide (PI) at a concentration of 50 µg/mL and incubated at 4°C in the dark for 30 min. Finally, flow cytometry was employed to examine PI signal.

**Apoptosis assay by flow cytometry**

Flow cytometry was performed with PI and FITC-labeled Annexin V (Beyotime, China) to detect phosphatidylserine externalization as an endpoint indicator of apoptosis as the manufacturer’s instructions describe.

---

![Figure 5: The correlation of ING5 protein expression with clinicopathological features of lung cancers.](image)

**Figure 5:** The correlation of ING5 protein expression with clinicopathological features of lung cancers. Tissue lysate was loaded and probed with anti-ING5 antibody with β-tubulin as an internal control in normal tissue (N, n = 20) and lung cancer (C, n = 57) by Western blot. The densitometric analysis showed higher ING5 expression in normal tissue than in lung cancer (A–C, p < 0.05). ING5 expression was not related to age or tumor size (D and E), p > 0.05. ING5 was hypoexpressed in adenocarcinoma (Ad), in comparison to squamous cell carcinoma and small cell carcinoma (F, p < 0.05). The data is expressed as mean ± standard error; *p < 0.05.
Figure 6: Immunohistochemical staining in lung cancer and adjacent normal lung tissues. Note: ING5 is distributed to the nucleus or cytoplasm and Caspase-3 protein is located in the cytoplasm, at the same time p53 and ki-67 is distributed to the nucleus. ING5 was expressed in pseudo-stratified columnar epithelium (A), alveolar epithelial cells, macrophage (B), squamous cell carcinoma (C, D), adenocarcinoma (E, F, G), large cell carcinoma (H), and small cell carcinoma (I). p53 (J), ki-67 (K) and Caspase-3 (L) were strongly expressed in lung cancer. Kaplan-Meier curves relating to the cumulative survival rate of the patients with lung cancer were analyzed according to nuclear (M) \( p = 0.637 \) or cytoplasmic (N) \( p = 0.183 \) ING5 expression status.
Table 1: Relationship between nuclear ING5 expression and clinicopathological parameters of lung cancers

| Clinicopathological features       | n   | Nuclear ING5 expression | PR (%) | P value |
|-----------------------------------|-----|-------------------------|--------|---------|
|                                   |     | − | + | ++ | +++ | |
| Sex                              |     | − | + | ++ | +++ | |
| Female                           | 214 | 35 | 65 | 71 | 43  | 83.6 | 0.452 |
| Male                             | 440 | 79 | 141| 137| 83  | 82.0 | |
| Age(years)                       |     | − | + | ++ | +++ | |
| < 65                             | 363 | 57 | 120| 119| 67  | 84.2 | 0.781 |
| ≥ 65                             | 291 | 57 | 86 | 89 | 59  | 80.4 | |
| Tumor size (cm)                  |     | − | + | ++ | +++ | |
| < 3                              | 211 | 31 | 62 | 67 | 51  | 85.3 | 0.184 |
| ≥ 3                              | 408 | 56 | 143| 138| 71  | 86.3 | |
| Histological classification      |     | − | + | ++ | +++ | |
| Squamous cell carcinoma          | 288 | 33 | 102| 90 | 63  | 88.5 | 0.001 |
| Adenocarcinoma                   | 317 | 58 | 90 | 110| 59  | 81.7 | |
| Large cell carcinoma             | 28  | 13 | 8 | 6 | 1   | 53.5 | |
| Small cell carcinoma             | 21  | 12 | 4 | 2 | 3   | 42.9 | |
| Lymphatic invasion               |     | − | + | ++ | +++ | |
| −                                | 488 | 84 | 154| 156| 94  | 82.8 | 0.752 |
| +                                | 159 | 29 | 50 | 51 | 29  | 81.8 | |
| Venous invasion                  |     | − | + | ++ | +++ | |
| −                                | 114 | 49 | 12 | 22 | 31  | 57.0 | 0.223 |
| +                                | 18  | 11 | 0 | 4 | 3   | 38.9 | |
| Lymph node metastasis            |     | − | + | ++ | +++ | |
| −                                | 395 | 76 | 119| 125| 75  | 80.8 | 0.512 |
| +                                | 250 | 38 | 82 | 82 | 48  | 84.8 | |
| UICC staging                     |     | − | + | ++ | +++ | |
| I–II                             | 506 | 86 | 158| 167| 95  | 83.0 | 0.844 |
| III–IV                           | 144 | 26 | 47 | 41 | 30  | 81.9 | |
| ki-67 expression                 |     | − | + | ++ | +++ | |
| −                                | 60  | 31 | 6 | 12 | 11  | 48.3 | 0.042 |
| + ~ +++                          | 70  | 27 | 6 | 14 | 23  | 61.4 | |
| CPP32 expression                 |     | − | + | ++ | +++ | |
| −                                | 30  | 15 | 4 | 4 | 7   | 50.0 | 0.770 |
| + ~ +++                          | 101 | 44 | 8 | 22 | 27  | 56.4 | |
| p53 expression                   |     | − | + | ++ | +++ | |
| −                                | 72  | 29 | 10| 16 | 17  | 59.7 | 0.462 |
| + ~ +++                          | 60  | 31 | 2 | 10 | 17  | 48.3 | |
| Cytoplasmic ING5 expression       |     | − | + | ++ | +++ | |
| −                                | 101 | 50 | 20| 14 | 17  | 50.5 | < 0.001 |
| + ~ +++                          | 553 | 64 | 186| 194| 109 | 88.4 | |

Abbreviations, PR, positive rate; UICC, Union Internationale Contre le Cancer.
| Clinicopathological features               | n     | −      | +      | ++     | +++    | PR (%) | P value |
|-------------------------------------------|-------|--------|--------|--------|--------|--------|---------|
| Sex                                       |       |        |        |        |        |        |         |
| Female                                    | 214   | 40     | 60     | 85     | 29     | 81.3   | 0.253   |
| Male                                      | 440   | 61     | 128    | 188    | 63     | 86.1   |         |
| Age(years)                                |       |        |        |        |        |        |         |
| < 65                                      | 363   | 43     | 109    | 153    | 58     | 88.1   | 0.025   |
| ≥ 65                                      | 291   | 58     | 79     | 120    | 34     | 80.0   |         |
| Tumor size(cm)                            |       |        |        |        |        |        |         |
| < 3                                       | 211   | 47     | 56     | 79     | 29     | 77.7   | 0.104   |
| ≥ 3                                       | 408   | 53     | 125    | 182    | 48     | 87.0   |         |
| Histological classification               |       |        |        |        |        |        | < 0.001 |
| Squamous cell carcinoma                   | 288   | 22     | 95     | 122    | 49     | 92.4   |         |
| Adenocarcinoma                            | 317   | 55     | 82     | 142    | 38     | 82.6   |         |
| Large cell carcinoma                      | 28    | 12     | 7      | 7      | 2      | 57.1   |         |
| Small cell carcinoma                      | 21    | 12     | 4      | 2      | 3      | 42.8   |         |
| Lymphatic invasion                        |       |        |        |        |        |        | 0.044   |
| −                                         | 488   | 65     | 143    | 207    | 73     | 86.7   |         |
| +                                         | 159   | 34     | 43     | 65     | 17     | 78.6   |         |
| Venous invasion                           |       |        |        |        |        |        | 0.149   |
| −                                         | 114   | 68     | 9      | 24     | 13     | 40.4   |         |
| +                                         | 18    | 7      | 2      | 7      | 2      | 61.1   |         |
| Lymph node metastasis                     |       |        |        |        |        |        | 0.046   |
| −                                         | 395   | 76     | 107    | 160    | 52     | 84.9   |         |
| +                                         | 250   | 25     | 78     | 109    | 38     | 90.0   |         |
| UICC staging                              |       |        |        |        |        |        | 0.109   |
| I–II                                      | 506   | 69     | 146    | 223    | 68     | 88.9   |         |
| III–IV                                    | 144   | 31     | 42     | 49     | 22     | 78.4   |         |
| ki-67 expression                          |       |        |        |        |        |        | 0.370   |
| −                                         | 60    | 37     | 5      | 14     | 4      | 38.3   |         |
| + ~ +++                                   | 70    | 38     | 6      | 16     | 10     | 45.7   |         |
| CPP32 expression                          |       |        |        |        |        |        | 0.005   |
| −                                         | 30    | 24     | 2      | 3      | 1      | 80.0   |         |
| + ~ +++                                   | 101   | 51     | 9      | 28     | 13     | 49.5   |         |
| p53 expression                            |       |        |        |        |        |        | 0.134   |
| −                                         | 72    | 44     | 7      | 16     | 5      | 38.9   |         |
| + ~ +++                                   | 60    | 31     | 4      | 15     | 10     | 48.3   |         |

Abbreviations, PR, positive rate; UICC, Union Internationale Contre le Cancer.
stored at −80 °C until being used. Informed consent was obtained from all subjects and the study was approved by the Ethics Committee of Jinzhou Medical University and China Medical University.

Xenograft models

BALB/c nude (nu/nu) mice of 6–8 weeks were bred and used for implantation. The animals were maintained under specific pathogen-free conditions, and food and water were supplied ad libitum. Housing and all procedures involving animals were performed according to protocols approved in compliance with the Committee for Animal Experiments Guidelines on Animal welfare of Jinzhou Medical University. Subcutaneous xenografts were established by injection of 1 × 10^6 tumor cells/mouse to the axilla (n = 20/group). Tumor growth was then monitored for 49 days. Until the end of the experiment, mice were anesthetized, photographed, and sacrificed. The tissues recovered were subjected to further analysis. For each tumor, measurements were made using calipers, and tumor volumes were calculated as follows: length × width × depth × 0.52. The part of tumors were subsequently fixed in 4% paraformaldehyde for 24 h, and then embedded in paraffin.

Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)

Total RNA was extracted from tissue and cells using Qiagen RNeasy mini kit and subsequently subjected to cDNA synthesis using Avian Myeloblastosis Virus transcriptase and random primer (Takara, Otsu, Japan). We carried out real-time RT-PCR using SYBR Premix Ex Taq™ II kit. According to the Genbank (NM_032329.4), oligonucleotide primers for ING3 were designed as follows: forward: 5ʹ- GGAGATGATTGGCTGTG-3ʹ and reverse: 5ʹ- CTTTTGGGTT TCGTGTA-3ʹ (614-759, 146bp). The primers for the internal control, GAPDH, were forward: F: 5ʹ- CAATGACCCCTTCATTGACC-3ʹ and reverse: 5ʹ- TGGAAGATGGTGATGGGATT-3ʹ (201-335, 135bp; NM_002046.3).

Western blot

The denatured protein was separated on a sodium lauryl sulfate (SDS) -polyacrylamide gel (12% acrylamide) and transferred to Hybond membrane, which was then blocked overnight in 5% milk in tris buffered saline with Tween 20 (TBST). For immunoblotting, the membrane was incubated with primary antibody for 1 h (Supplementary Table 1). Then, it was rinsed by TBST and incubated with IgG conjugated to horseradish peroxidase for 1 h. Bands were visualized with X-ray film by ECL-Plus detection reagents (Santa cruz). The densitometric quantification was performed with a GAPDH or β-tubulin control using Scion Image software.
Tissue microarray (TMA) and immunohistochemistry (IHC)

Representative areas of solid tumors were identified in HE stained sections of the selected tumor cases and a 2 mm-in-diameter tissue core per donor block was punched out and transferred to a recipient block with a maximum of 48 cores using a Tissue Microarrayer (AZUMAYA KIN-1, Tokyo, Japan). IHC was performed using intermittent irradiation in a microwave oven as described previously [34]. After each treatment, the slides were washed with TBST three times for 1 min. After counterstained with Mayer’s hematoxylin, the sections were dehydrated, cleared and mounted. Omission of the primary antibody was used as a negative control.

We considered the nuclear or cytoplasmic distribution of ING5 protein for statistical analysis in lung cancer. One hundred cells were randomly selected and counted from 5 representative fields of each section blindly by two independent observers (Zhao S and Zheng HC). The inconsistent data were confirmed by both persons until final agreements were reached. The expression positivity was graded and counted as follows: 0 = negative; 1 = 1–50%; 2 = 50–74%; 3 ≥ 75%. The staining intensity score was graded as follows: 1 = weak; 2 = intermediate; and 3 = strong. The scores for ING5 positivity and staining intensity were multiplied to obtain a final score, which determines their expression as (− = 0; + = 1–2; ++ = 3–5; +++ = 6–9).

Terminal digoxigenin-labeled dUTP nick-end labeling (TUNEL)

Cell apoptosis was assessed using TUNEL, a method that is based on the specific binding O-TdT to the 3-OH ends of DNA, ensuring the synthesis of a polydeoxynucleotide polymer. For this purpose, ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon) was employed according to the recommendation. Omission of the working strength TdT enzyme was considered as a negative control.

Statistical analysis

Statistical evaluation was performed using Spearman correlation test to analyze the rank data and using Mann-Whitney U to differentiate the means of different groups. Kaplan-Meier survival plots were generated and comparisons between survival curves were made with the log-rank statistic. $p < 0.05$ was considered as statistically significant. SPSS 10.0 software was employed to analyze all data.

ACKNOWLEDGMENTS AND FUNDING

This study was supported by President Fund of Jinzhou Medical University (XZJJ20140201; XZJJ20140203), Liaoning BaiQianWan Talents Program, A Project Supported by Scientific Research Fund of Liaoning Provincial Education Department (LJQ2014093); a Key Scientific and Technological Project of Liaoning Province (2015408001) and National Natural Scientific Foundation of China (81472544).

CONFLICTS OF INTEREST

The authors have declared that no competing interests exist.

REFERENCES

1. Kodama M, Kodama T, Murakami M. Oncogene activation and tumor suppressor gene inactivation find their sites of expression in the changes in time and space of the age-adjusted cancer incidence rate. In Vivo. 2000; 14:725–734.
2. Gunduz M, Demircan K, Gunduz E, Katase N, Tamamura R, Nagatsuka H. Inhibitor of Growth(ING) family: a emerging molecular target for cancer therapy. J Hard Tiss Biol. 2008; 17:1–10.
3. Soliman MA, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci. 2007; 32: 509–519.
4. Wang Y, Wang J, Li G. Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett. 2006; 580:3787–3793.
5. Unoki M, Kumamoto K, Takenoshita S, Harris CC. Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci. 2009; 100:1173–1179.
6. Champigne KS, Saksouk N, Peña PV, Johnson K, Ullah M, Yang XJ, Côté J, Kutateladze TG. The crystal structure of the ING5 PHD finger in complex with an H3K4me3 histone peptide. Proteins. 2008; 72:1371–1376.
7. Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, Champagne N, Côté J, Yang XJ. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol. 2008; 28:6828–6843.
8. Doyon Y, Cayrou C, Ullah M, Landry AJ, Côté V, Selleck W, Lane WS, Tan S, Yang XJ, Côté J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006; 21:51–64.
9. Doyon Y, Cayrou C, Ullah M, Landry AJ, Côté V, Selleck W, Lane WS, Tan S, Yang XJ, Côté J. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003; 63:2373–2378.
10. Shah S, Smith H, Feng X, Rancourt DE, Riabowol K. ING function in apoptosis in diverse model systems. Biochem Cell Biol. 2009; 87:117–125.
11. Zhang F, Bäumer N, Rode M, Ji P, Zhang T, Berdel WE, Müller-Tidow C. The inhibitor of growth protein 5 (ING5)
depends on INCA1 as a co-factor for its antiproliferative effects. PLoS One. 2011; 6:e21505.

12. Qi L, Zhang Y. Truncation of inhibitor of growth family protein 5 effectively induces senescence, but not apoptosis in human tongue squamous cell carcinoma cell line. Tumour Biol. 2014; 35:3139–3144.

13. Gou WF, Shen DF, Yang XF, Zhao S, Liu YP, Sun HZ, Su RJ, Luo JS, Zheng HC. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression. Oncotarget. 2015; 6:19552–19579. doi: 10.18632/oncotarget.3735.

14. Borkosky SS, Gunduz M, Beder L, Tsujigiwa H, Tamamura R, Gunduz E, Katase N, Rodriguez AP, Sasaki A, Nagai N, Nagatsu K. Allelic loss of the ING gene family loci is a frequent event in ameloblastoma. Oncol Res. 2010; 18:509–518.

15. Cengiz B, Gunduz E, Gunduz M, Beder LB, Tamamura R, Bagci C, Yamanaka N, Shimizu K, Nagatsuka H. Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int J Cancer. 2010; 127:2088–2094.

16. Li X, Nishida T, Noguchi A, Zheng Y, Takahashi H, Takano Y. Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2010; 136:1573–1583.

17. Zheng HC, Xia P, Xu XY, Takahashi H, Yang X, Masuda S, Takano Y. Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. Int J Cancer. 2010; 127:2088–2094.

18. Xing YN, Yang X, Xu XY, Zheng Y, Xu HM, Takano Y, Zheng HC. The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression. Hum Pathol. 2011; 42:424–433.

19. Cancer facts and figures. American Cancer Society. 2014 edition.

20. Kennedy S, Baerlocher MO. Screening for lung cancer. CMAJ. 2014; 186:E296.

21. Zhang F, Zhang X, Meng J, Zhao Y, Liu X, Liu Y, Wang Y, Li Y, Sun Y, Wang Z, Mei Q, Zhang T. ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer. Oncotarget. 2015; 6:16239–16252. doi:10.18632/oncotarget.3842.